Exploring the Synergistic Effects of CDK4/6 and PI3K Inhibitors in PIK3CA Mutant Breast Cancer
CDK4/6 inhibitors have transformed the landscape of hormone receptor-positive breast cancer treatment by targeting abnormal cell cycles. However, resistance remains a challenge, prompting exploration of PI3K inhibitors and genetic mutations to enhance efficacy. Understanding these dynamics and the tumor microenvironment’s role is vital for advancing personalized therapies and improving patient outcomes. Understanding CDK4/6 Inhibitors in […]
3 minute read